We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
Read MoreHide Full Article
Edwards Lifesciences (EW - Free Report) benefits from the huge untapped potential in the structural heart device market. Yet, persistent forex woes and rising costs do not bode well. The stock carries a Zacks Rank #3 (Hold)
Edwards Lifesciences registered year-over-year growth in both earnings and revenues during the third quarter. The company registered strong underlying growth across all product groups. Adjusted EPS grew despite aggressive investment in R&D and commercial infrastructure to support new therapies.
Critical Care sales were up 3% on an underlying basis in the third quarter of 2022. Sales growth was driven by increased adoption of the broad portfolio of smart recovery products, including FloTrac and ClearSight sensors with unique hypotension prediction index algorithms. Additionally, demand for the HemoSphere monitoring platform remains strong.
Edwards Lifesciences expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
In the third quarter, the company’s Surgical Structural Heart sales improved 8.2% on an underlying basis. The company continues to witness strong momentum of the RESILIA portfolio globally as it bolsters the overall body of evidence, including four abstracts recently presented at the European Association for Cardiothoracic Surgery Annual Meeting in Milan. Edwards Lifesciences continues to believe that physicians value the features and benefits of this advanced tissue technology for both aortic and mitral surgical valve replacement procedures. The company also noted that the adoption of the MITRIS valve launched in the United States in April 2022 now represents the majority of the mitral valve sales in this region.
Edwards Lifesciences expects underlying sales growth for 2022 in the mid-single-digit range, driven by market growth and the adoption of premium technologies.
On the flip side, Edwards Lifesciences’ revenues and earnings per share for the third quarter missed the Zacks Consensus Estimate. U.S. TAVR sales were impacted by slower-than-expected improvement in hospital staffing and temporary contrast agent shortages. Selling, general and administrative expenses rose 3.5% year over year, driven by the resumption of in-person commercial activities. These developments drove operating costs by 10%, building pressure on the company’s bottom line.
The choppy market conditions due to the continued foreign exchange impact and COVID-related hospital staffing issues are concerning. The company has lowered its sales outlook for full-year 2022, taking these macroeconomic challenges into account.
In the past year, Edwards Lifesciences has underperformed its industry. The stock has lost 39.8% compared with the 23.5% decline of the industry.
Key Picks
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Progyny Inc. (PGNY - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 4.2% compared with the industry’s 24.5% decline in the past year.
Progyny, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 21.1%. PGNY’s earnings surpassed estimates in all the trailing four quarters, the average beat being 233.75%.
PGNY has lost 23% compared with the industry’s 24.5% decline in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 21.7% against the industry’s 4.6% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
Edwards Lifesciences (EW - Free Report) benefits from the huge untapped potential in the structural heart device market. Yet, persistent forex woes and rising costs do not bode well. The stock carries a Zacks Rank #3 (Hold)
Edwards Lifesciences registered year-over-year growth in both earnings and revenues during the third quarter. The company registered strong underlying growth across all product groups. Adjusted EPS grew despite aggressive investment in R&D and commercial infrastructure to support new therapies.
Critical Care sales were up 3% on an underlying basis in the third quarter of 2022. Sales growth was driven by increased adoption of the broad portfolio of smart recovery products, including FloTrac and ClearSight sensors with unique hypotension prediction index algorithms. Additionally, demand for the HemoSphere monitoring platform remains strong.
Edwards Lifesciences expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
In the third quarter, the company’s Surgical Structural Heart sales improved 8.2% on an underlying basis. The company continues to witness strong momentum of the RESILIA portfolio globally as it bolsters the overall body of evidence, including four abstracts recently presented at the European Association for Cardiothoracic Surgery Annual Meeting in Milan. Edwards Lifesciences continues to believe that physicians value the features and benefits of this advanced tissue technology for both aortic and mitral surgical valve replacement procedures. The company also noted that the adoption of the MITRIS valve launched in the United States in April 2022 now represents the majority of the mitral valve sales in this region.
Edwards Lifesciences Corporation Price
Edwards Lifesciences Corporation price | Edwards Lifesciences Corporation Quote
Edwards Lifesciences expects underlying sales growth for 2022 in the mid-single-digit range, driven by market growth and the adoption of premium technologies.
On the flip side, Edwards Lifesciences’ revenues and earnings per share for the third quarter missed the Zacks Consensus Estimate. U.S. TAVR sales were impacted by slower-than-expected improvement in hospital staffing and temporary contrast agent shortages. Selling, general and administrative expenses rose 3.5% year over year, driven by the resumption of in-person commercial activities. These developments drove operating costs by 10%, building pressure on the company’s bottom line.
The choppy market conditions due to the continued foreign exchange impact and COVID-related hospital staffing issues are concerning. The company has lowered its sales outlook for full-year 2022, taking these macroeconomic challenges into account.
In the past year, Edwards Lifesciences has underperformed its industry. The stock has lost 39.8% compared with the 23.5% decline of the industry.
Key Picks
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Progyny Inc. (PGNY - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 4.2% compared with the industry’s 24.5% decline in the past year.
Progyny, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 21.1%. PGNY’s earnings surpassed estimates in all the trailing four quarters, the average beat being 233.75%.
PGNY has lost 23% compared with the industry’s 24.5% decline in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 21.7% against the industry’s 4.6% decline in the past year.